JOHNSON & JOHNSON
JNJNYSETrading Snapshot
- Day Range
- $258.45 – $263.05
- 52-Week Range
- $169.92 – $274.90
- Volume
- $9.36B
- Avg Volume
- $10.93B
- Shares Outstanding
- 2.41B
- Next Earnings
- Oct 3, 2026
Fundamentals Snapshot
- Annual Revenue
- $94.19B
- Last Q Revenue
- $25.31B
- P/E Ratio
- 29.8
- P/S Ratio
- 6.4x
- EPS (TTM)
- $8.62
- Dividend Yield
- 2.01%
Why Investors Own JNJ
- ✓High-growth profile — revenue up +25.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 62% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About JOHNSON & JOHNSON
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Uncover the latest developments among dow jones stocks in today's session.
Stay informed about the performance of the dow jones index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
How a 65-Year-Old Turned a $950,000 401(k) Rollover Into a $4,500 Monthly Paycheck Without Buying an Annuity
Pulling $54,000 a year from a $950,000 rollover IRA sounds like a math problem, but the real trap is hidden in the yield tier you choose and what it quietly does to your principal over time.
What Johnson & Johnson (JNJ)'s OTTAVA FDA Win and Talc Deal Shift Mean For Shareholders
In recent months, Johnson & Johnson reported strong Q2 2026 results, received FDA De Novo authorization for its OTTAVA soft-tissue robotic surgery system, advanced its RYBREVANT FASPRO oncology franchise with an FDA Priority Review, announced a US$5.50 billion talc settlement framework, and agreed to collaborate with Sail Biomedicines on in vivo CAR-T therapies. Together with leadership changes in its Innovative Medicine unit and new MedTech and electrophysiology partnerships, these...
What Analysts Really Pressed LLY On This Quarter
Eli Lilly's growth is huge, but on its latest call, analysts tested whether the next chapter can possibly live up to the last one.
Johnson & Johnson vs. Medtronic: Which Healthcare Stock Is Better Positioned After Earnings?
Johnson & Johnson (NYSE:JNJ) delivered another strong quarter in fiscal Q2 2026, with reported sales increasing 6.6% year over year to $25.31 billion and surpassing analysts’ average estimate of around $25.05 billion. Adjusted earnings per share reached $2.90, also exceeding estimates of $2.85. The healthcare giant raised its full-year outlook and said it remains on […]
The IRS Just Gave 65-Year-Olds a New $6,000 Deduction. These 3 ETFs Turn the Tax Break Into Monthly Income
Turning 65 comes with a quiet IRS bonus most retirees overlook, and the way you deploy it in the next few months could determine whether your retirement generates real monthly cash or simply keeps pace with inflation.